Neoadjuvant PSMA-RLT in Oligometastatic PCa

Who May Qualify: - Oligometastatic PCa diagnosed using \[68Ga\]Ga-PSMA-11 imaging defined as M1a and/or M1b positive with ≤5 osseous metastases and/or M1c ≤3 lung metastases - Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1 - Patients must have adequate bone marrow reserve: WBC ≥1.5 x 109 /L, platelet count at least 100 x 109 /L and Haemoglobin ≥9 g/dL. - Patients must have adequate renal function with eGFR ≥ 50mL/min/1.73m2 using the Modification of Diet Renal Disease (MDRD) equation and an Albumin level of ≥2.5 g/dL. - Patients must be able to sign willing to sign a consent form Form Who Should NOT Join This Trial: - Concomitant participation in any other interventional trial - Concurrent severe oncologic and medical conditions that result in patients not having a life expectancy of longer than the duration of the trial. - Nonmetastatic PCa on \[68Ga\]Ga-PSMA-11 imaging - \>5 osseous metastases on \[68Ga\]Ga-PSMA-11 imaging - Visceral metastases, apart from lungs - Age \> 75 years. - Ongoing or previous androgen deprivation therapy with agonist or antagonist therapies. - Presence of clinically relevant somatic or psychiatric diseases that might interfere with the objectives and assessments of the study. - Complete urinary out-flow obstruction or severe unmanageable urinary incontinence Always talk to your doctor about whether this trial is right for you.